胰高血糖素样肽-1受体激动剂停药在超重和肥胖无2型糖尿病患者中较高。

IF 5.4 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes, Obesity & Metabolism Pub Date : 2025-01-02 DOI:10.1111/dom.16151

Gregory J. Grosicki PhD, J. Graham Thomas PhD, Nikhil V. Dhurandhar PhD, Holly Lofton MD, Steven B. Heymsfield MD, Satya S. Jonnalagadda PhD

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Glucagon-like peptide-1 receptor agonists discontinuation is higher in individuals with overweight and obesity without type 2 diabetes

查看原文本刊更多论文

Glucagon-like peptide-1 receptor agonists discontinuation is higher in individuals with overweight and obesity without type 2 diabetes

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Diabetes, Obesity & Metabolism 医学-内分泌学与代谢

CiteScore

10.90

自引率

6.90%

发文量

319

审稿时长

3-8 weeks

期刊介绍： Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.